A nonprofit that often puts drug makers on edge with reports about the value of medicines may become still more controversial with plans to sound off about “unjustified price increases.”
The Institute for Clinical and Economic Review, which has become influential as a sort of cost-effectiveness watchdog for the pharmaceutical industry, expects to issue an annual report on price hikes thanks to a fresh round of backing from the Laura and John Arnold Foundation.
About the Author Reprints
